Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study

Aim Previously, we reported on the efficacy and safety of guanfacine extended‐release (GXR) in Japanese adults with attention‐deficit/hyperactivity disorder (ADHD) from a phase 3, double‐blind, placebo‐controlled, randomized trial. In this exploratory post hoc analysis, we assessed the efficacy and/...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychopharmacology reports 2021-03, Vol.41 (1), p.26-39
Main Authors: Naya, Noriyuki, Sakai, Chika, Okutsu, Daiki, Kiguchi, Ryo, Fujiwara, Masakazu, Tsuji, Toshinaga, Iwanami, Akira
Format: Article
Language:English
Subjects:
adult
Adults
Age
Attention deficit hyperactivity disorder
Blood pressure
Double-blind studies
Drug dosages
Electrocardiography
guanfacine extended‐release
Hyperactivity
Impulsivity
Mental disorders
Original
Population
Quality of life
safety
Teenagers
treatment efficacy
Vital signs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Previously, we reported on the efficacy and safety of guanfacine extended‐release (GXR) in Japanese adults with attention‐deficit/hyperactivity disorder (ADHD) from a phase 3, double‐blind, placebo‐controlled, randomized trial. In this exploratory post hoc analysis, we assessed the efficacy and/or safety of GXR in the following subgroups: ADHD‐combined (ADHD‐C) and ADHD‐predominantly inattentive (ADHD‐I) subtypes, age (≥31,
ISSN:2574-173X
2574-173X
DOI:10.1002/npr2.12152